Clinical Trials Logo
  1. Home
  2. Other
  3. NCT05783921

A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma

Metastatic Squamous Cell Carcinoma Clinical Trial

Official title:
A Randomized, Open, Multicenter Phase 1/Phase 2 Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma

Clinical Trial Summary

To evaluate the efficacy and safety of TQB2618 injection combined with Penpulimab and chemotherapy in the first-line treatment of relapsed/metastatic head and neck squamous cell carcinoma compared to Penpulimab combined chemotherapy. Progression-free survival (PFS) and objective response rate (ORR) were the primary efficacy endpoints.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05783921
Study type Interventional
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact
Status Recruiting
Phase Phase 1/Phase 2
Start date May 23, 2023
Completion date January 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04858269 - First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients Phase 2
Recruiting NCT04894370 - Combination of Spartalizumab, mDCF and Radiotherapy in Patients With Metastatic Squamous Cell Anal Carcinoma Phase 2
Not yet recruiting NCT06357858 - ASTX727 and Nivolumab in Squamous Cell Carcinoma of the Head and Neck Phase 1
Active, not recruiting NCT03283605 - Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas Phase 1/Phase 2
Recruiting NCT06236425 - TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC Phase 1
Completed NCT03847519 - Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer Phase 1/Phase 2
Active, not recruiting NCT03381183 - IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma Phase 1